Cargando…

The predictive capacity and additional prognostic power of N-terminal pro-B-type natriuretic peptide in Chinese elderly with chronic heart failure

OBJECTIVE: This study was conducted to research the prognostic utility of N-terminal pro-B-type natriuretic peptide (NT-proBNP), compare the utility of the Seattle Heart Failure Score (SHFS) with NT-proBNP, develop a risk-evaluation model based on NT-proBNP, assess the associations of NT-proBNP with...

Descripción completa

Detalles Bibliográficos
Autores principales: Fu, Shihui, Xie, Leixing, Li, Dongyun, Ye, Ping, Luo, Leiming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4315566/
https://www.ncbi.nlm.nih.gov/pubmed/25670892
http://dx.doi.org/10.2147/CIA.S77417
_version_ 1782355497106538496
author Fu, Shihui
Xie, Leixing
Li, Dongyun
Ye, Ping
Luo, Leiming
author_facet Fu, Shihui
Xie, Leixing
Li, Dongyun
Ye, Ping
Luo, Leiming
author_sort Fu, Shihui
collection PubMed
description OBJECTIVE: This study was conducted to research the prognostic utility of N-terminal pro-B-type natriuretic peptide (NT-proBNP), compare the utility of the Seattle Heart Failure Score (SHFS) with NT-proBNP, develop a risk-evaluation model based on NT-proBNP, assess the associations of NT-proBNP with patient characteristics, and screen for decisive factors of NT-proBNP in Chinese elderly with chronic heart failure (CHF). PATIENTS AND METHODS: There were 306 patients (≥60 years) with CHF chosen as study subjects. Each one received an assessment of NT-proBNP on serum. The end point was all-cause mortality during a mean follow-up period of 471 days. RESULTS: Subjects had a median age of 85 (60–100) years, a median NT-proBNP of 1,743.4 pg/mL, and a median SHFS of 1.87. During the follow-up period, 104 deaths occurred. NT-proBNP was significantly related to mortality (odds ratio 1.603, 95% confidence interval 1.407–1.826; P<0.001) and the significance persisted after full adjustment (odds ratio 1.282, 95% confidence interval 1.103–1.489; P=0.001). Age, New York Heart Association class IV CHF, plasma albumin, and neutrophils/lymphocytes were also independent predictors for mortality (P<0.05 for all). NT-proBNP and the SHFS showed similar predictive capacities (0.736 versus 0.796, P=0.105). The addition of NT-proBNP to the SHFS (0.818 versus 0.796, P=0.168) generated marginal growth in the c-statistic. The model based on NT-proBNP consisting of all selected predictors in this study, including age, New York Heart Association class IV CHF, plasma albumin, neutrophils/lymphocytes, and NT-proBNP, had a moderately higher c-statistic compared with the SHFS (0.846 versus 0.796, P=0.066). NT-proBNP was bound with the SHFS (r=0.500, P<0.001). Characteristics regarding general condition, inflammation, and cardiac and renal function were the decisive factors of NT-proBNP (P<0.05 for all). CONCLUSION: As a comprehensive representation of the patient characteristics described earlier, NT-proBNP values provided significant prognostic power similar to the SHFS in Chinese elderly with CHF. A novel model based on NT-proBNP could offer help for risk stratification.
format Online
Article
Text
id pubmed-4315566
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-43155662015-02-10 The predictive capacity and additional prognostic power of N-terminal pro-B-type natriuretic peptide in Chinese elderly with chronic heart failure Fu, Shihui Xie, Leixing Li, Dongyun Ye, Ping Luo, Leiming Clin Interv Aging Original Research OBJECTIVE: This study was conducted to research the prognostic utility of N-terminal pro-B-type natriuretic peptide (NT-proBNP), compare the utility of the Seattle Heart Failure Score (SHFS) with NT-proBNP, develop a risk-evaluation model based on NT-proBNP, assess the associations of NT-proBNP with patient characteristics, and screen for decisive factors of NT-proBNP in Chinese elderly with chronic heart failure (CHF). PATIENTS AND METHODS: There were 306 patients (≥60 years) with CHF chosen as study subjects. Each one received an assessment of NT-proBNP on serum. The end point was all-cause mortality during a mean follow-up period of 471 days. RESULTS: Subjects had a median age of 85 (60–100) years, a median NT-proBNP of 1,743.4 pg/mL, and a median SHFS of 1.87. During the follow-up period, 104 deaths occurred. NT-proBNP was significantly related to mortality (odds ratio 1.603, 95% confidence interval 1.407–1.826; P<0.001) and the significance persisted after full adjustment (odds ratio 1.282, 95% confidence interval 1.103–1.489; P=0.001). Age, New York Heart Association class IV CHF, plasma albumin, and neutrophils/lymphocytes were also independent predictors for mortality (P<0.05 for all). NT-proBNP and the SHFS showed similar predictive capacities (0.736 versus 0.796, P=0.105). The addition of NT-proBNP to the SHFS (0.818 versus 0.796, P=0.168) generated marginal growth in the c-statistic. The model based on NT-proBNP consisting of all selected predictors in this study, including age, New York Heart Association class IV CHF, plasma albumin, neutrophils/lymphocytes, and NT-proBNP, had a moderately higher c-statistic compared with the SHFS (0.846 versus 0.796, P=0.066). NT-proBNP was bound with the SHFS (r=0.500, P<0.001). Characteristics regarding general condition, inflammation, and cardiac and renal function were the decisive factors of NT-proBNP (P<0.05 for all). CONCLUSION: As a comprehensive representation of the patient characteristics described earlier, NT-proBNP values provided significant prognostic power similar to the SHFS in Chinese elderly with CHF. A novel model based on NT-proBNP could offer help for risk stratification. Dove Medical Press 2015-01-27 /pmc/articles/PMC4315566/ /pubmed/25670892 http://dx.doi.org/10.2147/CIA.S77417 Text en © 2015 Fu et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Fu, Shihui
Xie, Leixing
Li, Dongyun
Ye, Ping
Luo, Leiming
The predictive capacity and additional prognostic power of N-terminal pro-B-type natriuretic peptide in Chinese elderly with chronic heart failure
title The predictive capacity and additional prognostic power of N-terminal pro-B-type natriuretic peptide in Chinese elderly with chronic heart failure
title_full The predictive capacity and additional prognostic power of N-terminal pro-B-type natriuretic peptide in Chinese elderly with chronic heart failure
title_fullStr The predictive capacity and additional prognostic power of N-terminal pro-B-type natriuretic peptide in Chinese elderly with chronic heart failure
title_full_unstemmed The predictive capacity and additional prognostic power of N-terminal pro-B-type natriuretic peptide in Chinese elderly with chronic heart failure
title_short The predictive capacity and additional prognostic power of N-terminal pro-B-type natriuretic peptide in Chinese elderly with chronic heart failure
title_sort predictive capacity and additional prognostic power of n-terminal pro-b-type natriuretic peptide in chinese elderly with chronic heart failure
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4315566/
https://www.ncbi.nlm.nih.gov/pubmed/25670892
http://dx.doi.org/10.2147/CIA.S77417
work_keys_str_mv AT fushihui thepredictivecapacityandadditionalprognosticpowerofnterminalprobtypenatriureticpeptideinchineseelderlywithchronicheartfailure
AT xieleixing thepredictivecapacityandadditionalprognosticpowerofnterminalprobtypenatriureticpeptideinchineseelderlywithchronicheartfailure
AT lidongyun thepredictivecapacityandadditionalprognosticpowerofnterminalprobtypenatriureticpeptideinchineseelderlywithchronicheartfailure
AT yeping thepredictivecapacityandadditionalprognosticpowerofnterminalprobtypenatriureticpeptideinchineseelderlywithchronicheartfailure
AT luoleiming thepredictivecapacityandadditionalprognosticpowerofnterminalprobtypenatriureticpeptideinchineseelderlywithchronicheartfailure
AT fushihui predictivecapacityandadditionalprognosticpowerofnterminalprobtypenatriureticpeptideinchineseelderlywithchronicheartfailure
AT xieleixing predictivecapacityandadditionalprognosticpowerofnterminalprobtypenatriureticpeptideinchineseelderlywithchronicheartfailure
AT lidongyun predictivecapacityandadditionalprognosticpowerofnterminalprobtypenatriureticpeptideinchineseelderlywithchronicheartfailure
AT yeping predictivecapacityandadditionalprognosticpowerofnterminalprobtypenatriureticpeptideinchineseelderlywithchronicheartfailure
AT luoleiming predictivecapacityandadditionalprognosticpowerofnterminalprobtypenatriureticpeptideinchineseelderlywithchronicheartfailure